Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin and Pioglitazone Extension Study in T2DM
NCT01028391Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sitagliptin + Pioglitazone with Pioglitazone + Placebo (2 arms). Primary endpoint: Change From Baseline in Hemoglobin A1c at 54 weeks. Started Sep 2007; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01028391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01028391.